With a focus on actionable insights and strategic value, The Business Research Company’s 2026 market reports include market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights.
How Large Could The AI In Clinical Trials Market Become By 2030 At A 43% CAGR?
The AI in clinical trials market has experienced substantial growth in recent years. It is forecast to grow from $9.16 billion in 2025 to $13.08 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 42.8%. This historical growth can be linked to factors such as increasing complexity in clinical trials, rising expenditure on research and development, the imperative for quicker drug development, an expansion in clinical data volumes, and the inherent limitations of traditional trial methods.
The AI in clinical trials market is poised for significant expansion in the coming years. It is projected to reach $54.71 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 43.0%. This anticipated growth is driven by the expansion of decentralized clinical trials, the increasing incorporation of real-world evidence, the advancement of precision medicine, growing regulatory approval for AI tools, and progress in healthcare analytics. Prominent trends expected in the forecast period include AI-driven patient recruitment, predictive trial outcome modeling, automated clinical data analysis, the integration of remote patient monitoring, and the embrace of adaptive trial designs.
Get A Free AI In Clinical Trials Market Sample With 2030 Forecast Insights:
AI In Clinical Trials Market Outlook: Key Driver Supporting Long-Term Growth
The increasing occurrence of chronic and infectious diseases is anticipated to drive the expansion of the AI in clinical trials market. A chronic disease is defined as an ailment persisting for three months or longer, with the potential to worsen over time. AI in clinical trials offers utility in developing diverse medications for managing chronic conditions. For example, a report from the UK-based Macmillan Cancer Support in August 2024 indicated that over 3 million individuals in the UK were living with cancer in 2024, a number forecast to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the growing frequency of chronic and infectious diseases is propelling the growth of the AI in clinical trials market.
Segmentation Of The AI In Clinical Trials Market: Key Categories Explained
The AI in clinical trials market covered in this report is segmented –
1) By Offering: Software, Services
2) By Process: Trial Design, Patient Selection, Site Selection, Patient Monitoring
3) By Technology: Machine Learning, Deep Learning, Supervised Learning, Other Technologies
4) By Application: Oncology, Neurological Diseases And Condition, Cardiovascular Diseases, Metabolic Diseases, Infectious Diseases, Immunology Diseases, Other Applications
5) By End-User: Pharmaceuticals And Biotechnology Companies, Contract Research Organizations, Other End-Users
Subsegments:
1) By Software: Clinical Trial Management Systems (CTMS), Data Analytics Software, Predictive Analytics Tools, Patient Recruitment And Retention Software, Real-World Evidence Platforms
2) By Services: Consulting Services, Data Management And Analysis Services, Training And Support Services, Regulatory Compliance Services
AI In Clinical Trials Market Evolving Trends: What Businesses Should Know
Major companies operating in the AI in clinical trials market are actively engaging in strategic partnerships to provide research tools and enhance workflow efficiency, leading to improved timelines and increased patient recruitment. These collaborations involve organizations capitalizing on each other’s distinct strengths and resources to secure reciprocal advantages and achieve shared success. An illustrative example occurred in February 2023, when a US-based pharmaceutical commercial company formed a partnership with Haystack Health, a US-based software development company. Through this alliance, their objective is to harness AI and Natural Language Processing (NLP) to accelerate clinical trials, boost patient recruitment, and decrease screen failure rates. This is achieved by employing clinical AI and pre-screening services, which often incur significant costs in both time and financial resources.
Who Competes In The AI In Clinical Trials Market? Major Companies Listed
Major companies operating in the AI in clinical trials market are ConcertAI Inc.; Owkin Inc.; AiCure Technologies Inc.; Ardigen S.A.; Unlearn.AI Inc.; PathAI Inc.; Exscientia plc; VeriSIM Life Inc.; Envisagenics Inc.; NURITAS Limited; BioSymetrics Inc.; Trials.AI Inc.; IQVIA Holdings Inc.; Euretos B.V.; Saama Technologies LLC; Deep 6 AI Inc.; Medidata Solutions Inc.; Antidote Technologies Inc.; Castor EDC B.V.; TrialSpark Inc.; Phesi S.A.; CluePoints NV
Read The Complete AI In Clinical Trials Market Forecast Report Through 2030:
AI In Clinical Trials Market Regional Ranking: Which Geography Comes First?
North America was the largest region in the AI in clinical trials market in 2025. The regions covered in the AI in clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.
